Pavitra Dewda | Clinical Pharmacology | Best Researcher Award

Dr. Pavitra Dewda | Clinical Pharmacology | Best Researcher Award

Dr. Pavitra Dewda, GSK – GlaxoSmithKline, Belgium

Dr. Pavitra Dewda is a seasoned Global Medical Director with over a decade of experience in the pharmaceutical and biotechnology industries, specializing in medical strategy, clinical development, and vaccine lifecycle management. Currently at GlaxoSmithKline, she leads global medical strategies for vaccines, focusing on hepatitis, pertussis, and pneumococcal vaccines. Previously, she held leadership roles at Merck KGaA and Sanofi Pasteur, driving initiatives in medical affairs and scientific engagement. Dr. Dewda has been recognized with multiple global awards for her contributions to vaccine education, regulatory affairs, and medical strategy. 🌍💉💊📈👩‍🔬

 

Publication Profile

Scopus

Education & Professional Development

 

Dr. Pavitra Dewda holds an MD from Padmashree Dr. D.Y. Patil University, Pune (2011), and an MBBS from Maharashtra University of Medical Science (2005). Her strong educational foundation in medicine has enabled her to excel in the global pharmaceutical industry. With a passion for medical strategy and vaccine development, Dr. Dewda continues to enhance her expertise through ongoing professional development in clinical affairs, regulatory management, and public health. Her education forms the bedrock for her impactful career in global medical leadership. 🎓💉📚👩‍⚕️

Executive Career Synopsis & Highlights

Dr. Pavitra Dewda is a seasoned global medical leader, currently serving as Global Medical Director at GlaxoSmithKline (GSK) since December 2022. She leads global medical lifecycle accountability for key vaccine portfolios, including hepatitis and pertussis, and drives strategic partnerships, advocacy, and medical strategy. Previously, she was General Manager Medical at GSK India, where she led medical operations, secured regulatory approvals, and executed successful vaccine launches. Dr. Dewda has also held leadership roles at Sanofi and Merck KGaA, excelling in medical affairs, strategic initiatives, and digital transformation, receiving multiple awards for her innovative contributions. 💉🌍🎓

 

Research Focus

Dr. Pavitra Dewda’s research focuses primarily on vaccinology 🦠💉, infectious diseases 🦠, medical affairs 🩺, and fertility medicine 👶. She has contributed to studies on hepatitis A and B vaccination for at-risk adults in Europe, emphasizing healthcare professionals’ knowledge, attitudes, and practices. Dr. Dewda also co-authored research on vaccinating healthcare providers in India, showcasing the importance of immunization in healthcare settings. Additionally, she has explored fertility treatments 🌱, particularly in in vitro fertilization (IVF) outcomes, demonstrating her expertise in both public health and reproductive health. Her work blends clinical research and medical strategy.

 

Publication Top Notes

  • “Knowledge, Attitudes, and Practices of European Healthcare Professionals towards Hepatitis A and Hepatitis B Vaccination in at-Risk Adults”Vaccines, 2023, 11(11), 1645 🦠💉 | Cited by: 1
  • “A Modern Perspective on Vaccinating Healthcare Service Providers in India: A Narrative Review”Infectious Diseases and Therapy, 2022, 11(1), 81–99 🩺💉 | Cited by: 5
  • “Association between progesterone elevation on the day of human chronic gonadotropin trigger and pregnancy outcomes after fresh embryo transfer in in vitro fertilization/intracytoplasmic sperm injection cycles”Frontiers in Endocrinology, 2018, 9(APR), 201 👶⚗️ | Cited by: 23

 

 

Amita Datta-Mannan | Clinical Pharmacology Award | Best Researcher Award

Dr. Amita Datta-Mannan | Clinical Pharmacology | Best Researcher Award

Dr. Amita Datta-Mannan Eli Lilly & Company, United States

Amita Datta-Mannan is a seasoned pharmaceutical scientist and leader with nearly two decades of experience spanning multiple therapeutic areas. Her career has been marked by significant contributions in drug discovery and development, particularly in translational medicine and clinical pharmacology. She has held diverse roles, including leading large interdisciplinary teams and overseeing strategic initiatives to advance therapeutic modalities such as biologics, antibodies, and small molecules through various phases of clinical trials.

Publication profile

Orcid

Scopus

Education:

Amita Datta-Mannan’s academic journey includes rigorous training and education in pharmaceutical sciences. She holds advanced degrees and certifications relevant to her field, providing a solid foundation for her career in drug discovery and development. Her educational background underscores her expertise in clinical pharmacology, pharmacokinetics, and the intricate processes involved in bringing novel therapeutics from bench to bedside.

Research Focus:

Amita Datta-Mannan’s research focuses on advancing understanding in clinical pharmacology and drug metabolism. Her work spans across multiple therapeutic areas, with particular emphasis on autoimmune diseases, oncology, and rare disorders. She is passionate about integrating scientific advancements into clinical practice, aiming to improve patient outcomes through innovative therapeutic approaches.

Professional Journey:

Amita Datta-Mannan’s professional journey is characterized by progressive leadership roles in pharmaceutical research and development. She has led cross-functional teams, driving the strategy and execution of clinical trials from early-phase development to regulatory approval. Her career highlights include contributions to the design and implementation of clinical protocols, safety assessments, and pharmacological studies that have shaped therapeutic advancements in the industry.

Honors & Awards:

Throughout her career, Amita Datta-Mannan has been recognized for her contributions and achievements in pharmaceutical science. She has received prestigious honors and awards that acknowledge her leadership, innovation, and impact on advancing therapeutic modalities. These accolades underscore her dedication to excellence and her significant role in shaping the future of drug discovery and development.

Publications Noted & Contributions:

Title: Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A (LY3509754): A Phase I Randomized Placebo‐Controlled Study

Journal: Clinical Pharmacology & Therapeutics

Publication Date: May 2024

DOI: 10.1002/cpt.3185

Contributors: Amita Datta‐Mannan; Arie Regev; David E. Coutant; Andrew J. Dropsey; Joanne Foster; Spencer Jones; Josh Poorbaugh; Carsten Schmitz; Evan Wang; Michael E. Woodman

Title: Advancing the utilization of real‐world data and real‐world evidence in clinical pharmacology and translational research—Proceedings from the ASCPT 2023 preconference workshop

Journal: Clinical and Translational Science

Publication Date: April 2024

DOI: 10.1111/cts.13785

Contributors: Jing Liu; Karen Rowland‐Yeo; Almut Winterstein; Simon Dagenais; Qi Liu; Jeffrey S. Barrett; Rui Zhu; Cyrus Ghobadi; Amita Datta‐Mannan; Joy Hsu et al.

Title: Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals

Journal: PLOS ONE

Publication Date: April 17, 2024

DOI: 10.1371/journal.pone.0293703

Contributors: Amita Datta-Mannan; Satish Rojekar; Hiuwan Choi; Zhaoyan Jin; Ling Liu; Jirong Lu; David J. Stokell; Anthony T. Murphy; Kenneth W. Dunn; Michelle M. Martinez et al.

Title: Impact of COVID‐19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective

Journal: Clinical Pharmacology & Therapeutics

Publication Date: March 27, 2024

DOI: 10.1002/cpt.3242

Contributors: Mohamed‐Eslam F. Mohamed; Sandhya Girish; Rita Humeniuk; Silpa Nuthalapati; Amit Desai; Amita Datta‐Mannan; Ferdous Gheyas; Jitendra Kanodia; Sravanthi Cheeti; Tong Zhu